Login/Sign Up
₹51000*
₹43350*
MRP ₹51000
15% CB
₹7650 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Online payment accepted
Whats That
About Lorbriqua 25 mg Tablet 10's
Lorbriqua 25 mg Tablet 10's belongs to the group of medicines that inhibit an enzyme called anaplastic lymphoma kinase (ALK). It is used to treat adults with advanced stages of lung cancer called non-small cell lung cancer (NSCLC). Non-small cell lung cancer is a disease in which malignant (cancer) cells form in the lung tissues. There are several types of non-small cell lung cancer. Smoking is the major risk factor for non-small cell lung cancer.
Lorbriqua 25 mg Tablet 10's contains the active substance Lorlatinib, a medicine used to treat adults with advanced stages of a form of lung cancer called non-small cell lung cancer (NSCLC). It works by inhibiting a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK. Lorbriqua 25 mg Tablet 10's is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase.
Always use this medicine as your doctor has told you or per the package leaflet. You must keep to your doctor's instructions to get the maximum benefit. In some cases, you may experience common side effects such as diarrhoea, constipation, joint pain, weight gain, headache, rash, and muscle pain. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if you experience these side effects persistently.
Consult your doctor before taking Lorbriqua 25 mg Tablet 10's if you are pregnant or breastfeeding. Lorbriqua 25 mg Tablet 10's may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Lorbriqua 25 mg Tablet 10's as it could lead to increased dizziness. Lorbriqua 25 mg Tablet 10's is not recommended for children below 18 years as safety and effectiveness have not been established. Lorbriqua 25 mg Tablet 10's is listed as pregnancy category D. Because Lorbriqua 25 mg Tablet 10's can cause harm to the fetus, women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Lorbriqua 25 mg Tablet 10's. Consult your doctor if you are breastfeeding; your doctor will decide whether Lorbriqua 25 mg Tablet 10's can be taken by breastfeeding mothers or not. Keep your doctor informed about your health condition and medicines to rule out any side effects. Lorbriqua 25 mg Tablet 10's may affect male fertility. Talk to your doctor about fertility preservation before taking Lorbriqua 25 mg Tablet 10's.
Uses of Lorbriqua 25 mg Tablet 10's
Directions for Use
Medicinal Benefits
Lorbriqua 25 mg Tablet 10's contains the active substance Lorlatinib, a medicine used to treat adults with advanced stages of a form of lung cancer called non-small cell lung cancer (NSCLC). Lorbriqua 25 mg Tablet 10's is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase. It works by inhibiting a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK.
Storage
Drug Warnings
Consult your doctor before taking Lorbriqua 25 mg Tablet 10's if you are pregnant or breastfeeding. Lorbriqua 25 mg Tablet 10's may cause tiredness and dizziness, so drive with caution. Avoid consuming alcohol with Lorbriqua 25 mg Tablet 10's as it could lead to increased dizziness. Lorbriqua 25 mg Tablet 10's is not recommended for children below 18 years as safety and effectiveness have not been established. Lorbriqua 25 mg Tablet 10's is listed as pregnancy category D. Because Lorbriqua 25 mg Tablet 10's can cause harm to the fetus, women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Lorbriqua 25 mg Tablet 10's. Consult your doctor if you are breastfeeding; your doctor will decide whether the Lorbriqua 25 mg Tablet 10's can be taken by breastfeeding mothers or not. Keep your doctor informed about your health condition and medicines to rule out any side effects. Lorbriqua 25 mg Tablet 10's may affect male fertility. Talk to your doctor about fertility preservation before taking Lorbriqua 25 mg Tablet 10's.
Diet & Lifestyle Advise
Habit Forming
Therapeutic Class
Product Substitutes
We provide you with authentic, trustworthy and relevant information
Lorbriqua 25 mg Tablet 10's contains the active substance Lorlatinib, which inhibits a type of enzyme called tyrosine kinase and triggers the death of cancer cells in patients with alterations in genes for ALK. Lorbriqua 25 mg Tablet 10's is only given to patients whose disease is due to an alteration in the gene for ALK tyrosine kinase.
Lorlatinib belongs to the kinase inhibitor class of drugs. Lorlatinib is a drug used to treat a kind of non-small cell lung cancer (NSCLC) that has spread to other places of the body in adults. It works by preventing the malfunctioning protein from causing cancer cells to multiply.
Lorbriqua 25 mg Tablet 10's should be stopped when a person faces a serious side effect that affects life quality. Otherwise, it would be best to keep taking Lorbriqua 25 mg Tablet 10's until your doctor asks you to stop it.
Avoid smoking before starting the treatment while taking Lorbriqua 25 mg Tablet 10's as smoking might alter the effectiveness of Lorbriqua 25 mg Tablet 10's.
In elderly patients, the risk of side effects is greater. For the elderly, dose adjustment might be required, or your doctor might prescribe any other medication safe for the elderly.
You should complete the full course of Lorbriqua 25 mg Tablet 10's as your doctor prescribes. After completing the full course of Lorbriqua 25 mg Tablet 10's will work. It would help if you took Lorbriqua 25 mg Tablet 10's at the right dose, right times and for the right number of days.
Detecting lung cancer in its early stages, when it is most treatable, is critical to survival. Early tumours have a cure rate of 85-90 per cent, but this depends on other factors.
Drug-Drug Interactions Checker List
Special Advise
You will have blood tests before you start treatment and during your treatment. These tests check the level of cholesterol, triglycerides and the enzymes amylase or lipase in your blood before you start treatment with Lorbriqua 25 mg Tablet 10's and regularly during treatment. You will have blood tests before you start treatment and during your treatment. These tests check the level of cholesterol, triglycerides and the enzymes amylase or lipase in your blood before you start treatment with Lorbriqua 25 mg Tablet 10's and regularly during treatment.
Disease/Condition Glossary
Non-small cell lung cancer (NSCLC): Non-small cell lung cancer (NSCLC) is a disease in which malignant (cancer) cells form in the lung tissues. There are several types of non-small cell lung cancer. Smoking is the major risk factor for non-small cell lung cancer.
Have a query?